ACT appointed to conduct Phase IIa trial of POLB 001
Specialist blood cancer trials organisation Accelerating Clinical Trials Limited (ACT) has signed an agreement with biopharmaceutical company Poolbeg Pharma to conduct the Phase IIa clinical trial of POLB 001.
The Phase IIa first-in-patient open-label, single-arm trial is titled TOPICAL (Trial of Prevention of ImmunoCytokine Adverse events in Myeloma). The study aims to investigate the safety and efficacy of POLB 001, including its ability to reduce the incidence of Cytokine Release Syndrome (“CRS”) in approximately 30 relapsed/refractory multiple myeloma patients receiving an approved bispecific antibody.
The agreement with ACT also means Poolbeg Pharma has secured the supply of an approved bispecific antibody drug for the trial at no cost.
The trial will be led by Dr Emma Searle, Consultant Haematologist at The Christie NHS Foundation Trust, Honorary Senior Lecturer at the University of Manchester, as well as Chair of the British Society of Haematology Research and Grants Committee. The Christie, a leading cancer research institute based in Manchester, and a number of other leading UK specialist cancer centres will participate.
POLB 001 could ‘transform the delivery of cancer immunotherapies’
This agreement represents an advanced stage of trial preparation, with interim data anticipated in summer 2026. The company states that POLB 001 could potentially transform the cancer immunotherapy field by expanding administration from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, CRS. POLB 001 could increase the number of patients that can receive these life-saving treatments, increasing the market opportunity.
Dr Paul Sherrington, CEO of Accelerating Clinical Trials said: “At ACT we work hand-in-hand with the haematological community to accelerate the delivery of clinical trials of new therapies, leveraging our wide network of research centres in the UK. We look forward to completing this study with POLB 001 which holds great potential to transform the cancer immunotherapy field and address this critical unmet medical need.”
Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, added: “The signing of this agreement, and the supply of the approved bispecific antibody at no cost to the company, are major milestones for the upcoming POLB 001 Phase IIa trial. The trial is at an advanced stage of preparation and remains on track to deliver data in 2026, we look forward to sharing the data with prospective partners. With a cash runway into 2027, and multiple near-term clinical inflection points, we believe that we are well positioned to deliver value for our shareholders.”
“We are optimistic about the potential of POLB 001 to transform the delivery of cancer immunotherapies by expanding administration away from specialist centralised cancer centres and into the community setting, closer to patients’ homes. This shift could make these life-saving treatments more widely accessible. POLB 001 has the potential to make cancer immunotherapies safer by reducing the incidence of potentially life-threatening cancer immunotherapy-induced cytokine release syndrome.”
By Bruno Quinney, Content Team, DDW
